Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04565509 · ClinicalTrials.gov registry record · NA

Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic

A NA study of COVID-19 and Intellectual Disability, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
1,143
Enrollment target
3
Study locations

NCT04565509: Completed NA study of COVID-19 and Intellectual Disability, sponsored by Washington University School of Medicine.

NCT04565509 is a NA study of COVID-19 and Intellectual Disability that has completed, run by Washington University School of Medicine. The registered enrollment target is 1,143 participants, below the 38,461-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04565509, a NA study of COVID-19 and Intellectual Disability, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
1,143 participants
Enrollment target
3
Study locations

Study Summary

The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally the perceptions of COVID-19 and identify facilitators and barriers to help with the adoption of testing in other parts of the US and the necessary strategies to address other mitigation strategies including vaccination.

Primary Outcome

Assuming the binomial distribution for each primary outcome, generalized estimating equation (GEE) models with logit link function were utilized to investigate the primary outcome changes across the weeks. The denominators for the enrollment and test rate per school were the total number of staff and students; and the total number of consented participants for a specific week, respectively. For the weeks after randomization, the GEE model included the indicator of week, group indicator, and the

Interventions

  • DIAGNOSTIC_TEST COVID-19 Testing
  • BEHAVIORAL Focus Groups
  • BEHAVIORAL Standard Messaging
  • BEHAVIORAL Enhanced Messaging
  • BEHAVIORAL Fuzzy Cognitive Mapping

Study Locations (3)

Missouri

  • University of Missouri - Kansas City
  • Special School District - St Louis

Maryland

  • Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Baltimore

Trial Details

FieldValue
Enrollment Target 1,143 participants
Start Date 2020-11-20
Est. Completion 2024-03-29
Phase NA

What the finished NCT04565509 record still lists

NCT04565509 is an interventional study that assigns participants to a tested intervention. Its 1,143 participants enrollment target places it among the larger protocols in the corpus, below the 38,461-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which COVID-19 Testing is the first listed.

NCT04565509 reports a single indexed study location in Missouri, Maryland.

Frequently Asked Questions

What is clinical trial NCT04565509 about?

NCT04565509 is a clinical study titled "Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic". The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally...

What is the current status of trial NCT04565509?

This trial is currently completed. It is a NA study. The enrollment target is 1,143 participants. The study started on 2020-11-20. Estimated completion is 2024-03-29.

What conditions does trial NCT04565509 study?

This clinical trial studies the following conditions: COVID-19, Intellectual Disability, Developmental Disability, Child Development Disorder.

What interventions are being tested in trial NCT04565509?

The interventions under investigation include: COVID-19 Testing (DIAGNOSTIC_TEST), Focus Groups (BEHAVIORAL), Standard Messaging (BEHAVIORAL), Enhanced Messaging (BEHAVIORAL), Fuzzy Cognitive Mapping (BEHAVIORAL).

Who is sponsoring clinical trial NCT04565509?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04565509 being conducted?

This trial has 3 study locations across Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04565509's enrollment target sits among peer trials

1,143 66th of 298 higher than 233 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06129864 · 1,145 participants · Phase 3

    A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  • NCT05894967 · 1,140 participants · NA

    Moderators and Mediators of Perceptual Learning

  • NCT06532487 · 1,140 participants · NA

    Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities

  • NCT06676319 · 1,147 participants · Phase 2

    Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04565509, the US trial registry maintained by the National Library of Medicine. NCT04565509 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.